119 related articles for article (PubMed ID: 22516806)
41. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.
Shinto E; Hase K; Hashiguchi Y; Sekizawa A; Ueno H; Shikina A; Kajiwara Y; Kobayashi H; Ishiguro M; Yamamoto J
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S414-21. PubMed ID: 24566864
[TBL] [Abstract][Full Text] [Related]
42. Multidrug resistance-associated protein 3 confers resistance to chemoradiotherapy for rectal cancer by regulating reactive oxygen species and caspase-3-dependent apoptotic pathway.
Yu Z; Zhang C; Wang H; Xing J; Gong H; Yu E; Zhang W; Zhang X; Cao G; Fu C
Cancer Lett; 2014 Oct; 353(2):182-93. PubMed ID: 25088576
[TBL] [Abstract][Full Text] [Related]
43. Outcomes in locally advanced rectal cancer with highly selective preoperative chemoradiotherapy.
Williamson JS; Jones HG; Davies M; Evans MD; Hatcher O; Beynon J; Harris DA;
Br J Surg; 2014 Sep; 101(10):1290-8. PubMed ID: 24924947
[TBL] [Abstract][Full Text] [Related]
44. Clinical significance of CD133 and hypoxia inducible factor-1α gene expression in rectal cancer after preoperative chemoradiotherapy.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Koike Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):323-32. PubMed ID: 20970309
[TBL] [Abstract][Full Text] [Related]
45. Clinical significance of LGR5 and CD44 expression in locally advanced rectal cancer after preoperative chemoradiotherapy.
Saigusa S; Inoue Y; Tanaka K; Toiyama Y; Matsushita K; Kawamura M; Okugawa Y; Hiro J; Uchida K; Mohri Y; Kusunoki M
Int J Oncol; 2012 Nov; 41(5):1643-52. PubMed ID: 22923071
[TBL] [Abstract][Full Text] [Related]
46. NPTX2 is associated with neoadjuvant therapy response in rectal cancer.
Karagkounis G; Thai L; DeVecchio J; Gantt GA; Duraes L; Pai RK; Kalady MF
J Surg Res; 2016 May; 202(1):112-7. PubMed ID: 27083956
[TBL] [Abstract][Full Text] [Related]
47. miR-519b-3p promotes responsiveness to preoperative chemoradiotherapy in rectal cancer patients by targeting ARID4B.
Luo J; Liu L; Zhou N; Shen J; Sun Q; Zhu Y; Chen M
Gene; 2018 May; 655():84-90. PubMed ID: 29477868
[TBL] [Abstract][Full Text] [Related]
48. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.
Lamas MJ; Duran G; Gomez A; Balboa E; Anido U; Bernardez B; Rana-Diez P; Lopez R; Carracedo A; Barros F
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):138-44. PubMed ID: 21167658
[TBL] [Abstract][Full Text] [Related]
49. Adjuvant chemoradiation plus intraoperative radiotherapy versus adjuvant chemoradiation alone in patients with locally advanced rectal cancer.
Zhang Q; Tey J; Yang Z; Li P; Peng L; Fu S; Huang G; Xiong F; Lu JJ
Am J Clin Oncol; 2015 Feb; 38(1):11-6. PubMed ID: 25616201
[TBL] [Abstract][Full Text] [Related]
50. Prognostic significance of DSG3 in rectal adenocarcinoma treated with preoperative chemoradiotherapy.
Chao TB; Li CF; Lin CY; Tian YF; Chang IW; Sheu MJ; Lee YE; Chan TC; He HL
Future Oncol; 2016 Jun; 12(12):1457-67. PubMed ID: 27040321
[TBL] [Abstract][Full Text] [Related]
51. What is the significance of a microscopically positive resection margin in the curative-intent treatment of rectal adenocarcinoma? A retrospective study.
Fekete Z; Muntean A; Irimie A; Hica S; Resiga L; Todor N; Nagy V
J BUON; 2013; 18(4):989-95. PubMed ID: 24344028
[TBL] [Abstract][Full Text] [Related]
52. C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery.
Toiyama Y; Inoue Y; Saigusa S; Kawamura M; Kawamoto A; Okugawa Y; Hiro J; Tanaka K; Mohri Y; Kusunoki M
Anticancer Res; 2013 Nov; 33(11):5065-74. PubMed ID: 24222151
[TBL] [Abstract][Full Text] [Related]
53. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
[TBL] [Abstract][Full Text] [Related]
54. Prognostic significance of circumferential resection margin following total mesorectal excision and adjuvant chemoradiotherapy in patients with rectal cancer.
Baik SH; Kim NK; Lee YC; Kim H; Lee KY; Sohn SK; Cho CH
Ann Surg Oncol; 2007 Feb; 14(2):462-9. PubMed ID: 17096053
[TBL] [Abstract][Full Text] [Related]
55. A functional biological network centered on XRCC3: a new possible marker of chemoradiotherapy resistance in rectal cancer patients.
Agostini M; Zangrando A; Pastrello C; D'Angelo E; Romano G; Giovannoni R; Giordan M; Maretto I; Bedin C; Zanon C; Digito M; Esposito G; Mescoli C; Lavitrano M; Rizzolio F; Jurisica I; Giordano A; Pucciarelli S; Nitti D
Cancer Biol Ther; 2015; 16(8):1160-71. PubMed ID: 26023803
[TBL] [Abstract][Full Text] [Related]
56. Trefoil factor 3 (TFF3) enhances the oncogenic characteristics of prostate carcinoma cells and reduces sensitivity to ionising radiation.
Perera O; Evans A; Pertziger M; MacDonald C; Chen H; Liu DX; Lobie PE; Perry JK
Cancer Lett; 2015 May; 361(1):104-11. PubMed ID: 25748388
[TBL] [Abstract][Full Text] [Related]
57. MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma.
Bibby BA; Reynolds JV; Maher SG
PLoS One; 2015; 10(7):e0134180. PubMed ID: 26221725
[TBL] [Abstract][Full Text] [Related]
58. High chloride channel accessory 1 expression predicts poor prognoses in patients with rectal cancer receiving chemoradiotherapy.
Chen TJ; He HL; Shiue YL; Yang CC; Lin LC; Tian YF; Chen SH
Int J Med Sci; 2018; 15(11):1171-1178. PubMed ID: 30123054
[No Abstract] [Full Text] [Related]
59. Aberrant expression of trefoil factor 3 is associated with colorectal carcinoma metastasis.
Huang YG; Li YF; Wang LP; Zhang Y
J Cancer Res Ther; 2013; 9(3):376-80. PubMed ID: 24125969
[TBL] [Abstract][Full Text] [Related]
60. Predictive markers of chemoradiotherapy for rectal cancer: comparison of biopsy specimens taken before and about 1 week after the start of chemoradiotherapy.
Suzuki T; Sadahiro S; Tanaka A; Okada K; Saito G; Kamijo A; Akiba T; Kawada S
Int J Clin Oncol; 2015 Dec; 20(6):1130-9. PubMed ID: 25833701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
